Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 5/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.37 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | SENP5 | Q96HI0 | 1/20 | 0.36 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.36 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38147003 | 1.00 | CXCR2 (0.56) | CXCR2DRD4KIFC1SLC6A5TRPV1 | |
| SCHEMBL23460921 | 1.00 | CXCR2 (0.56) | CXCR2DRD4KIFC1SLC6A5TRPV1 | |
| SCHEMBL23459904 | 0.91 | CXCR2 (0.58) | CXCR2DRD4KIFC1SLC6A5TRPV1 | |
| SCHEMBL25601618 | 0.91 | CXCR2 (0.58) | CXCR2DRD4KIFC1SLC6A5TRPV1 | |
| SCHEMBL25548794 | 0.90 | CXCR2 (0.45) | CXCR2KIFC1ALDH1A1GAAMAPT | |
| SCHEMBL25549506 | 0.90 | CXCR2 (0.45) | CXCR2KIFC1ALDH1A1GAAMAPT | |
| SCHEMBL25549217 | 0.90 | CXCR2 (0.45) | CXCR2KIFC1ALDH1A1GAAMAPT | |
| SCHEMBL23460793 | 0.89 | CXCR2 (0.44) | CXCR2KIFC1SLC6A5MMEACE | |
| SCHEMBL23460936 | 0.89 | CXCR2 (0.46) | CXCR2KIFC1PPARGPPARDALDH1A1 | |
| SCHEMBL38147005 | 0.89 | CXCR2 (0.44) | CXCR2KIFC1SLC6A5MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| WO-2021113806-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | CXCR2 1205/4885DRD4 4290/4885KIFC1 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.